Lei H Zhang

US Patent:

20230002459, Jan 5, 2023

Filed:

Oct 2, 2020

Appl. No.:

17/766083

Inventors:

- Brisbane CA, US
Lei Zhang - Davis CA, US

Assignee:

Sangamo Therapeutics, Inc. - Brisbane CA

International Classification:

C07K 14/47
A61K 48/00
A61P 25/28
C12N 15/86

Abstract:

The present disclosure provides zinc finger fusion proteins that inhibit expression of the prion gene in the nervous system, and methods of using the proteins to treat prion disease.

US Patent:

20200313227, Oct 1, 2020

Filed:

Mar 26, 2020

Appl. No.:

16/830285

Inventors:

- College Park MD, US
Eric D. WACHSMAN - Fulton MD, US
Boyang LIU - Columbia MD, US
Lei Zhang - Berwyn Heights MD, US
Dennis MCOWEN - WASHINGTON DC, US
Chunpeng YANG - Berwyn Heights MD, US

International Classification:

H01M 10/0525
H01M 2/16
H01M 4/38
H01M 4/1393
H01M 10/0565
H01M 10/0566

Abstract:

The present disclosure describes various types of batteries, including lithium-ion batteries having an anode assembly comprising: an anode comprising a first porous ceramic matrix having pores; and a ceramic separator layer affixed directly or indirectly to the anode; a cathode; an anode-side current collector contacting the anode; and anode active material comprising lithium located within the pores or cathode active material located within the cathode; wherein, the ceramic separator layer is located between the anode and the cathode, no electrically conductive coating on the pores contacts the separator layer, and in a fully charged state, lithium active material in the anode does not contact the separator layer. Also disclosed are methods of making and methods of using such batteries.

US Patent:

20150259740, Sep 17, 2015

Filed:

Sep 14, 2012

Appl. No.:

13/618589

Inventors:

Harvey Pollard - Potomac MD, US
Lei Zhang - Germantown MD, US
Ofer Eidelman - Bethesda MD, US
Robert J. Ursano - Kensington MD, US
He Li - Rockville MD, US
Tung-Pi Su - Taipei, TW
Kevin Ka-wang Wang - , US
Ronald L. Hayes - , US

International Classification:

C12Q 1/68
G01N 33/68

Abstract:

Life-threatening traumas such as terrorist attacks, war, disasters, mental or physical assault, severe accidents and violence frequently provoke emotional and behavioral disturbances known as post-traumatic stress disorder (PTSD) and suicide related thereto. Accurate diagnosis and treatment planning for PTSD and suicide remain difficult. The discovery of specific markers creates new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. The present invention provides a process of detection of P-11, UBE3A, STY1, EMAP-II, SIP1, ORC5L, DCX, SCYE protein in a biological sample of a subject suspected of suffering from PTSD and/or having suicidal tendencies, and provides additional PTSD markers which are specific to gender.